Making smart investment decisions in clinical research

Nick Bansback, Edward Keystone, James Robert O'Dell, Ciaran S. Phibbs, Keri Hannagan, Mary Brophy, Aslam Anis

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

A recent trial in rheumatoid arthritis found an inexpensive, but infrequently used, combination of therapies is neither inferior nor less safe than an expensive biologic drug. If the trial had been conducted over 10 years ago, arguably 100's of millions of dollars since spent on biologics could have been released to other, more effective treatments. Given the ever increasing number of trials proposed, this commentary uses the trial as an example to challenge payers and research funders to make smarter investments in clinical research to save potential future costs. Trial registration: NCT00405275 , registered 29 November 2006

Original languageEnglish (US)
Article number590
JournalTrials
Volume16
Issue number1
DOIs
StatePublished - Dec 29 2015

Fingerprint

Biological Products
Research
Rheumatoid Arthritis
Costs and Cost Analysis
Pharmaceutical Preparations
Therapeutics

Keywords

  • Economics
  • Randomized trials
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

Bansback, N., Keystone, E., O'Dell, J. R., Phibbs, C. S., Hannagan, K., Brophy, M., & Anis, A. (2015). Making smart investment decisions in clinical research. Trials, 16(1), [590]. https://doi.org/10.1186/s13063-015-1123-1

Making smart investment decisions in clinical research. / Bansback, Nick; Keystone, Edward; O'Dell, James Robert; Phibbs, Ciaran S.; Hannagan, Keri; Brophy, Mary; Anis, Aslam.

In: Trials, Vol. 16, No. 1, 590, 29.12.2015.

Research output: Contribution to journalComment/debate

Bansback, N, Keystone, E, O'Dell, JR, Phibbs, CS, Hannagan, K, Brophy, M & Anis, A 2015, 'Making smart investment decisions in clinical research', Trials, vol. 16, no. 1, 590. https://doi.org/10.1186/s13063-015-1123-1
Bansback N, Keystone E, O'Dell JR, Phibbs CS, Hannagan K, Brophy M et al. Making smart investment decisions in clinical research. Trials. 2015 Dec 29;16(1). 590. https://doi.org/10.1186/s13063-015-1123-1
Bansback, Nick ; Keystone, Edward ; O'Dell, James Robert ; Phibbs, Ciaran S. ; Hannagan, Keri ; Brophy, Mary ; Anis, Aslam. / Making smart investment decisions in clinical research. In: Trials. 2015 ; Vol. 16, No. 1.
@article{c7c90378f33346fa913685427bc4b3d2,
title = "Making smart investment decisions in clinical research",
abstract = "A recent trial in rheumatoid arthritis found an inexpensive, but infrequently used, combination of therapies is neither inferior nor less safe than an expensive biologic drug. If the trial had been conducted over 10 years ago, arguably 100's of millions of dollars since spent on biologics could have been released to other, more effective treatments. Given the ever increasing number of trials proposed, this commentary uses the trial as an example to challenge payers and research funders to make smarter investments in clinical research to save potential future costs. Trial registration: NCT00405275 , registered 29 November 2006",
keywords = "Economics, Randomized trials, Rheumatoid arthritis",
author = "Nick Bansback and Edward Keystone and O'Dell, {James Robert} and Phibbs, {Ciaran S.} and Keri Hannagan and Mary Brophy and Aslam Anis",
year = "2015",
month = "12",
day = "29",
doi = "10.1186/s13063-015-1123-1",
language = "English (US)",
volume = "16",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Making smart investment decisions in clinical research

AU - Bansback, Nick

AU - Keystone, Edward

AU - O'Dell, James Robert

AU - Phibbs, Ciaran S.

AU - Hannagan, Keri

AU - Brophy, Mary

AU - Anis, Aslam

PY - 2015/12/29

Y1 - 2015/12/29

N2 - A recent trial in rheumatoid arthritis found an inexpensive, but infrequently used, combination of therapies is neither inferior nor less safe than an expensive biologic drug. If the trial had been conducted over 10 years ago, arguably 100's of millions of dollars since spent on biologics could have been released to other, more effective treatments. Given the ever increasing number of trials proposed, this commentary uses the trial as an example to challenge payers and research funders to make smarter investments in clinical research to save potential future costs. Trial registration: NCT00405275 , registered 29 November 2006

AB - A recent trial in rheumatoid arthritis found an inexpensive, but infrequently used, combination of therapies is neither inferior nor less safe than an expensive biologic drug. If the trial had been conducted over 10 years ago, arguably 100's of millions of dollars since spent on biologics could have been released to other, more effective treatments. Given the ever increasing number of trials proposed, this commentary uses the trial as an example to challenge payers and research funders to make smarter investments in clinical research to save potential future costs. Trial registration: NCT00405275 , registered 29 November 2006

KW - Economics

KW - Randomized trials

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84951783538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951783538&partnerID=8YFLogxK

U2 - 10.1186/s13063-015-1123-1

DO - 10.1186/s13063-015-1123-1

M3 - Comment/debate

C2 - 26712327

AN - SCOPUS:84951783538

VL - 16

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 590

ER -